Systemic Juvenile Idiopathic Arthritis

The FDA has granted rare pediatric disease designation to a type IA prodrug of dexamethasone that targets CD206+ macrophages for the treatment of systemic juvenile idiopathic arthritis flares, according to a press release from PIF Partners.

Systemic juvenile idiopathic arthritis and adult-onset Still’s disease have been combined into one entity called Still’s disease in new recommendations document presented at the EULAR 2023 Congress.